Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) has announced a strategic collaboration with Every Cure, a nonprofit organization, to accelerate drug repurposing for cancer treatment. The partnership leverages POAI's extensive biobank of 150,000+ tumor samples across 130+ cancer types and AI-driven platform that can screen drugs against various tumor types.

Every Cure will utilize POAI's data from testing approximately 150 FDA-approved drugs on patient tumor samples. The nonprofit employs AI models, including knowledge graphs and large language models, to identify potential connections between existing drugs and diseases. The collaboration aims to expedite the discovery of new cancer treatment options while making healthcare more accessible and economically feasible.

Positive

• Access to extensive biobank of 150,000+ tumor samples across 130+ cancer types
• Partnership combines complementary AI capabilities for accelerated drug repurposing
• Potential to identify new cancer treatments at lower costs and faster timelines
• Validation of POAI's AI platform through previous successful drug repurposing efforts

Negative

• None.

Insights

Oncology Research Expert

POAI's AI-driven partnership with Every Cure to repurpose FDA-approved drugs could accelerate cancer treatment discovery while reducing costs substantially.

This strategic collaboration between Predictive Oncology and Every Cure represents a significant advancement in drug repurposing for cancer treatment. By combining POAI's extensive biobank of over 150,000 tumor samples across 130+ cancer types with Every Cure's AI repurposing technologies, the partnership aims to identify new applications for approximately 150 FDA-approved drugs.

The scientific approach is particularly compelling. POAI's platform allows for rapid screening of drugs against various tumor types to predict patient response, while Every Cure employs knowledge graphs and large language models to identify connections between existing drugs and diseases. This complementary AI integration could dramatically accelerate the typical drug development timeline.

Drug repurposing offers substantial advantages over traditional drug development. The typical new drug requires 10-15 years and $1-2 billion to reach market, whereas repurposing existing medications can be accomplished in months rather than decades, at a fraction of the cost. Additionally, repurposed drugs have established safety profiles, reducing risks to patients.

For cancer patients with limited treatment options, this initiative could potentially identify effective therapies from drugs already approved for other conditions. The collaboration specifically targets scenarios where standard treatment options have been exhausted, addressing a critical unmet need in oncology care while promoting more equitable and economically feasible healthcare solutions.

This partnership leverages POAI's proven track record in supporting drug discovery and development while aligning with Every Cure's mission to help the 300+ million people globally battling diseases with no approved treatments. The validation that POAI's platform has already successfully identified drugs for repurposing suggests this collaboration has tangible potential to deliver meaningful clinical results.

Collaboration builds upon positive results utilizing Predictive Oncology’s AI platform to identify new indications for existing drugs

PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced a strategic collaboration to identify and prioritize drugs for repurposing to improve patient outcomes and save lives.

Predictive Oncology has a longstanding commitment to supporting the best treatments for patients diagnosed with cancer, through both proprietary clinical assays and AI-driven machine learning (ML). These capabilities allow for the rapid screening of a drug against a broad range of tumor types, with the goal of predicting a patient’s response to an anti-cancer therapy. Predictive Oncology has a long and established track record of supporting various stages of drug discovery and development, enabling drug developers to expand and replenish their pipelines.

Every Cure is a nonprofit on a mission to save and improve lives with repurposed drugs– working to alleviate suffering for more than 300 million people globally who are battling diseases with no approved treatments. The organization leverages AI to identify matches between FDA-approved drugs and known diseases, pinpointing the most promising opportunities for drug repurposing and aiming to deliver treatments to patients in months rather than decades, at a fraction of the cost of new drug development.

“The synergy between each organization’s AI assets and expertise are clearly complementary in serving the intended purpose of accelerating drug repurposing while overcoming barriers to these efforts,” said Dr. Arlette Uihlein, SVP, Translational Medicine and Drug Discovery, Medical Director at Predictive Oncology. “As Every Cure scales its approach to meet these challenges, we believe we are the perfect partner, capable of generating data on patient tumor response to drugs in a fraction of the time and at far less cost than more traditional approaches.”

Every Cure seeks to use data generated by Predictive Oncology, which pairs patient tumor samples with approximately 150 FDA-approved drugs, each of which have been approved for at least one specific clinical indication. This repurposing effort allows for existing drugs to be used in new indications, which aligns closely with the strengths and capabilities of Predictive Oncology’s platform.

“The intersecting interests and expertise of our two organizations perfectly aligns with our drug repurposing efforts, seeking to identify treatments to be used when standard treatments options have been exhausted, while also promoting equitable and economically feasible healthcare,” said Every Cure’s Dr. David Fajgenbaum. “Collaborating with Predictive Oncology on this endeavor not only supports our mission but advances our cause.”

“This collaboration on drug repurposing leverages our unique assets and capabilities, most notably our vast biobank of more than 150,000 tumor samples across more than 130 different cancer types,” said Raymond F. Vennare, CEO of Predictive Oncology. “Together we believe we can make a meaningful difference in the lives of patients in need, and we are pleased to be able to assist Every Cure in advancing these efforts”

Every Cure’s AI models use knowledge graphs, large language models, and real-world medical data to identify and rank potential connections between existing drugs and diseases. Top-ranked opportunities are then rigorously evaluated by the experienced team at Every Cure, who determine what is needed to bring them safely to patients. In some cases, Every Cure generates additional pre-clinical or clinical evidence and engages with research partners, regulators, and patient organizations to maximize patient impact and ensure treatments reach those who need them. Predictive Oncology’s ML models use AI to predict patient tumor drug response, based on wet lab testing which accesses the thousands of human tumor samples and associated data housed at Predictive Oncology’s CLIA lab. One application of the platform, which has already been validated and deployed, has been used to identify drugs for repurposing.

About Every Cure
Every Cure is a nonprofit biotech organization committed to unlocking the potential of existing medicines to treat as many diseases as possible. By harnessing AI-driven platforms, rigorous preclinical and clinical testing, and global dissemination strategies, Every Cure accelerates the delivery of life-saving treatments to patients worldwide. Every Cure has been profiled on Good Morning America, USA Today, and the Wall Street Journal and selected as both an Audacious Project grantee from TED and a Founder’s Prize recipient from Elevate Prize Foundation. Learn more at www.everycure.org.

About Predictive Oncology
Predictive Oncology is on the cutting edge of the rapidly growing use of artificial intelligence and machine learning to expedite early drug discovery and enable drug development for the benefit of cancer patients worldwide. The company’s scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug , allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. Together with the company’s vast biobank of more than 150,000 assay-capable heterogenous human tumor samples, Predictive Oncology offers its academic and industry partners one of the industry’s broadest AI-based drug discovery solutions, further complimented by its wholly owned CLIA laboratory facility. Predictive Oncology is headquartered in Pittsburgh, PA.

Investor Relations Contact
Mike Moyer
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Forward-Looking Statements
Certain matters discussed in this release contain forward-looking statements. These forward- looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, changes in management, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the company disclaims any intent or obligation to update these forward-looking statements.

FAQ

What is the purpose of the collaboration between Predictive Oncology (POAI) and Every Cure?

The collaboration aims to identify and prioritize FDA-approved drugs for repurposing in cancer treatment, leveraging POAI's AI platform and tumor sample biobank to improve patient outcomes and save lives.

How many tumor samples and cancer types does Predictive Oncology (POAI) have in its biobank?

POAI maintains a biobank containing more than 150,000 tumor samples across more than 130 different cancer types.

How many FDA-approved drugs will be tested in POAI's drug repurposing program?

The program will test approximately 150 FDA-approved drugs that have been previously approved for at least one specific clinical indication.

What technology does Every Cure use for drug repurposing research?

Every Cure uses AI models including knowledge graphs, large language models, and real-world medical data to identify and rank potential connections between existing drugs and diseases.

How does Predictive Oncology's AI platform contribute to drug repurposing?

POAI's AI platform uses machine learning models to predict patient tumor drug response through wet lab testing of thousands of human tumor samples in their CLIA lab.